Otsuka Pharmaceutical Co., Ltd (Japan) 45%
P.T.Otsuka Indonesia (Indonesia) 10%
Feroz Family Karachi 30%
General Public (Including National Investment Trust) 15%
As per Finincial Times of March 24, 2014:
.............Today, TB has been mostly banished from the rich world aside from pockets of vulnerability among impoverished communities in cities such as London. But it remains one of the greatest public health risks in many low- and middle-income countries, where 95 per cent of fatalities occur. India, China, South Africa, Indonesia and Pakistan top the list in terms of volume of cases.
Efforts to tackle the disease are being complicated by the rise of drug-resistant strains – a consequence of poor management of existing medicines by doctors and poor compliance by patients. Special treatments are available to overcome drug-resistance but they are costlier and longer-lasting with more severe side effects and lower levels of effectiveness.
There was a breakthrough last year when US regulators approved a new treatment for multi-drug resistant TB (MDR-TB) by Johnson & Johnson, the first new TB medicine of any kind for 40 years. Another, from Otsuka of Japan is also on the launch pad.
While welcoming the new treatments, activists say they will not change the landscape on their own.